Literature DB >> 27903709

Eltrombopag, a potent stimulator of megakaryopoiesis.

Hana Raslova1, William Vainchenker1, Isabelle Plo2.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27903709      PMCID： PMC5479610          DOI： 10.3324/haematol.2016.153668

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  20 in total

1.  Update on eltrombopag for ITP.

Authors:  James B Bussel
Journal:  Oncology (Williston Park)       Date:  2009-11-30       Impact factor: 2.990

2.  Programmable 3D silk bone marrow niche for platelet generation ex vivo and modeling of megakaryopoiesis pathologies.

Authors:  Christian A Di Buduo; Lindsay S Wray; Lorenzo Tozzi; Alessandro Malara; Ying Chen; Chiara E Ghezzi; Daniel Smoot; Carla Sfara; Antonella Antonelli; Elise Spedden; Giovanna Bruni; Cristian Staii; Luigi De Marco; Mauro Magnani; David L Kaplan; Alessandra Balduini
Journal:  Blood       Date:  2015-01-09       Impact factor: 22.113

3.  Identification of the residues in the extracellular domain of thrombopoietin receptor involved in the binding of thrombopoietin and a nuclear distribution protein (human NUDC).

Authors:  Wei-Min Chen; Bo Yu; Qing Zhang; Peilin Xu
Journal:  J Biol Chem       Date:  2010-06-07       Impact factor: 5.157

4.  Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation.

Authors:  Michael Roth; Britta Will; Guillermo Simkin; Swathi Narayanagari; Laura Barreyro; Boris Bartholdy; Roni Tamari; Constantine S Mitsiades; Amit Verma; Ulrich Steidl
Journal:  Blood       Date:  2012-05-24       Impact factor: 22.113

5.  F104S c-Mpl responds to a transmembrane domain-binding thrombopoietin receptor agonist: proof of concept that selected receptor mutations in congenital amegakaryocytic thrombocytopenia can be stimulated with alternative thrombopoietic agents.

Authors:  Norma E Fox; Jihyang Lim; Rose Chen; Amy E Geddis
Journal:  Exp Hematol       Date:  2010-02-24       Impact factor: 3.084

6.  Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin.

Authors:  S Kimura; A W Roberts; D Metcalf; W S Alexander
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-03       Impact factor: 11.205

7.  Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome.

Authors:  Britta Will; Masahiro Kawahara; Julia P Luciano; Ingmar Bruns; Samir Parekh; Connie L Erickson-Miller; Manuel A Aivado; Amit Verma; Ulrich Steidl
Journal:  Blood       Date:  2009-08-26       Impact factor: 22.113

Review 8.  From hematopoietic stem cells to platelets.

Authors:  Y Chang; D Bluteau; N Debili; W Vainchenker
Journal:  J Thromb Haemost       Date:  2007-07       Impact factor: 5.824

9.  The non-peptide thrombopoietin receptor agonist eltrombopag stimulates megakaryopoiesis in bone marrow cells from patients with relapsed multiple myeloma.

Authors:  Jee-Yeong Jeong; Michelle S Levine; Nirmalee Abayasekara; Nancy Berliner; Jacob Laubach; Gary J Vanasse
Journal:  J Hematol Oncol       Date:  2015-04-16       Impact factor: 17.388

10.  High doses of romiplostim induce proliferation and reduce proplatelet formation by human megakaryocytes.

Authors:  Manuela Currao; Carlo L Balduini; Alessandra Balduini
Journal:  PLoS One       Date:  2013-01-24       Impact factor: 3.240
View more
  5 in total

1.  Exploring the Potential of Eltrombopag: Room for More?

Authors:  Francesco Tarantini; Cosimo Cumbo; Luisa Anelli; Antonella Zagaria; Maria Rosa Conserva; Immacolata Redavid; Giorgina Specchia; Pellegrino Musto; Francesco Albano
Journal:  Front Pharmacol       Date:  2022-05-23       Impact factor: 5.988

2.  Elucidating the Mechanism of Action of the Attributed Immunomodulatory Role of Eltrombopag in Primary Immune Thrombocytopenia: An In Silico Approach.

Authors:  Maria L Lozano; Cristina Segú-Vergés; Mireia Coma; María T Álvarez-Roman; José R González-Porras; Laura Gutiérrez; David Valcárcel; Nora Butta
Journal:  Int J Mol Sci       Date:  2021-06-27       Impact factor: 5.923

Review 3.  Transitioning patients with immune thrombocytopenia to second-line therapy: Challenges and best practices.

Authors:  Adam Cuker
Journal:  Am J Hematol       Date:  2018-04-15       Impact factor: 10.047

Review 4.  Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives.

Authors:  Nicola Vianelli; Giuseppe Auteri; Francesco Buccisano; Valentina Carrai; Erminia Baldacci; Cristina Clissa; Daniela Bartoletti; Gaetano Giuffrida; Domenico Magro; Elena Rivolti; Daniela Esposito; Gian Marco Podda; Francesca Palandri
Journal:  Ann Hematol       Date:  2022-02-24       Impact factor: 4.030

5.  Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study.

Authors:  Hanny Al-Samkari; Debbie Jiang; Terry Gernsheimer; Howard Liebman; Susie Lee; Matthew Wojdyla; Michael Vredenburg; Adam Cuker
Journal:  Br J Haematol       Date:  2022-02-18       Impact factor: 8.615
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.